Analyst says Incyte's pipeline makes it attractive takeover candidate Print E-mail
By M.E.Garza   
Tuesday, 15 May 2012 06:26
Goldman Sachs upgrades Incyte (NASDAQ: INCY) from Neutral to Buy with a price target of $29 (up from $21), suggesting a 26% premium from today's prices as the drug discovery company focused on developing proprietary small molecule drugs becomes the latest M&A target.

Those who follow Incyte Corporation, know that the company has a broad range of discovery capabilities in-house, including target validation, high-throughput screening, medicinal chemistry, computational chemistry, and pharmacological and ADME (absorption, distribution, metabolism and excretion) assessment. Its products include: INCB18424 (oral) for Prostate Cancer (Metastatic Prostate Cancer), Hematological Malignancies (Primary Myelofibrosis), Psoriasis and multiple myeloma; INCB28050 (oral) for Rheumatoid arthritis and Cancer; INCB13739 and INCB19602 for Type II Diabetes; INCB7839 for Breast cancer and Solid Tumors; INCB28060 and INCB24360 for Solid Cancers; and INCB8696 for Lupus Nephritis. 

Pfizer (NYSE: PFE) looks like it is getting its next blockbuster approved after an advisory panel voted 8-2 recommending approval of its rheumatoid arthritis drug tofacitinib and Goldman is reportedly more bullish about INCY due to the significant derisking of Incyte's key pipeline asset LY3009104.   In addition, INCY has seen a strong launch of Jakafi-- an indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post–polycythemia vera myelofibrosis and post–essential thrombocythemia myelofibrosis.

"104's potential was validated with the positive FDA panel vote this past week on Pfizer’s tofacitinib," the firm said.Goldman also sees Incyte as a more attractive M&A target given it has a marketed drug and a potential blockbuster pipeline asset.

Shares could be worth up to $37 in a takeover, Goldman Sachs estimates.

We note that this stock is highly shorted and share purchases by insiders have been on the rise.

The BioMedReports FDA Calendar shows a few upcoming milestones for the company over the next two years including news that a randomized Phase II trial of ruxolitinib in combination with capecitabine for patients with recurrent or treatment refractory metastatic pancreatic cancer (the RECAP trial) is expected to enroll approximately 130 patients by the end of 2012.  Results from the RESPONSE trial are expected in the second half of 2013.

Disclosure: None




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter